News

Cognis is a supplier of solutions and products based on renewable raw materials for the health and nutrition market as well as the cosmetics, detergents and cleaners industries.

Valeant Pharma said that, since last year, it has experienced a shortage of Oxsoralen products due to an unanticipated change in the supplier of the product’s active ingredient.

Dr Amphlett and Dr Lutz have played central roles in establishing ImmunoGen’s product development capabilities. These functions complement the company’s research capabilities in ImmunoGen’s advancement of its own

Dapagliflozin, an investigational compound, is a potential sodium-glucose cotransporter-2 (SGLT2) inhibitor currently in Phase 3 trials under joint development by Bristol-Myers Squibb Company and AstraZeneca. The study also

As per the agreement, OMJPI is expected to get an exclusive worldwide license to manufacture, develop and commercialise several Metabolex programs which are currently at the preclinical stage.

Wellington currently operates from an 116,000sqft facility that is equipped with process automation equipment and is fully compliant with the latest federal regulations. About 80 employees made the

The two new programs added are expected to address the development of four compounds which target different subpopulations of patients suffering from DMD. To access these new programs,

Eribulin is an investigational anticancer agent discovered and developed by Eisai. Eisai filed simultaneous regulatory applications for approval of Eribulin to the health authorities in the US, Japan

The acceptance letter confirms that the Chemistry, Manufacturing and Controls (CMC) response filed by NexMed is acceptable for the final, 150-day review cycle, during which regulatory reviewers are